New Results
SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems
Daniel Blanco-Melo, Benjamin E. Nilsson-Payant, Wen-Chun Liu, Rasmus Møller, Maryline Panis, David Sachs, Randy A. Albrecht, Benjamin R. tenOever
doi: https://doi.org/10.1101/2020.03.24.004655
Daniel Blanco-Melo
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
2Virus Engineering Center for Therapeutics and Research (VECToR), Icahn School of Medicine at Mount Sinai, New York, USA
Benjamin E. Nilsson-Payant
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
2Virus Engineering Center for Therapeutics and Research (VECToR), Icahn School of Medicine at Mount Sinai, New York, USA
Wen-Chun Liu
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, USA
Rasmus Møller
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
2Virus Engineering Center for Therapeutics and Research (VECToR), Icahn School of Medicine at Mount Sinai, New York, USA
Maryline Panis
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
2Virus Engineering Center for Therapeutics and Research (VECToR), Icahn School of Medicine at Mount Sinai, New York, USA
David Sachs
4Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
Randy A. Albrecht
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, USA
Benjamin R. tenOever
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA
2Virus Engineering Center for Therapeutics and Research (VECToR), Icahn School of Medicine at Mount Sinai, New York, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, USA

- Supplementary Table 1[supplements/004655_file02.xlsx]
- Supplementary Table 2[supplements/004655_file03.xlsx]
- Supplementary Table 3[supplements/004655_file04.xlsx]
- Supplementary Table 4[supplements/004655_file05.xlsx]
- Supplementary Table 5[supplements/004655_file06.xlsx]
- Supplementary Table 6[supplements/004655_file07.xlsx]
Posted March 24, 2020.
SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems
Daniel Blanco-Melo, Benjamin E. Nilsson-Payant, Wen-Chun Liu, Rasmus Møller, Maryline Panis, David Sachs, Randy A. Albrecht, Benjamin R. tenOever
bioRxiv 2020.03.24.004655; doi: https://doi.org/10.1101/2020.03.24.004655
SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems
Daniel Blanco-Melo, Benjamin E. Nilsson-Payant, Wen-Chun Liu, Rasmus Møller, Maryline Panis, David Sachs, Randy A. Albrecht, Benjamin R. tenOever
bioRxiv 2020.03.24.004655; doi: https://doi.org/10.1101/2020.03.24.004655
Subject Area
Subject Areas
- Biochemistry (7567)
- Bioengineering (5522)
- Bioinformatics (20782)
- Biophysics (10325)
- Cancer Biology (7978)
- Cell Biology (11635)
- Clinical Trials (138)
- Developmental Biology (6602)
- Ecology (10200)
- Epidemiology (2065)
- Evolutionary Biology (13611)
- Genetics (9539)
- Genomics (12844)
- Immunology (7919)
- Microbiology (19538)
- Molecular Biology (7657)
- Neuroscience (42081)
- Paleontology (308)
- Pathology (1257)
- Pharmacology and Toxicology (2201)
- Physiology (3267)
- Plant Biology (7038)
- Synthetic Biology (1951)
- Systems Biology (5426)
- Zoology (1116)